KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Amortization - Goodwill (2017 - 2024)

Teva Pharmaceutical Industries (TEVA) has disclosed Amortization - Goodwill for 7 consecutive years, with $600.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Amortization - Goodwill changed N/A year-over-year to $600.0 million, compared with a TTM value of $1.0 billion through Sep 2025, changed 0.0%, and an annual FY2024 reading of $1.3 billion, up 82.86% over the prior year.
  • Amortization - Goodwill was $600.0 million for Q3 2024 at Teva Pharmaceutical Industries, up from $400.0 million in the prior quarter.
  • Across five years, Amortization - Goodwill topped out at $4.6 billion in Q3 2020 and bottomed at $400.0 million in Q2 2024.
  • Average Amortization - Goodwill over 4 years is $1.4 billion, with a median of $722.5 million recorded in 2022.
  • The sharpest move saw Amortization - Goodwill skyrocketed 192.56% in 2020, then tumbled 42.86% in 2024.
  • Year by year, Amortization - Goodwill stood at $4.6 billion in 2020, then crashed by 71.91% to $1.3 billion in 2022, then tumbled by 46.15% to $700.0 million in 2023, then dropped by 14.29% to $600.0 million in 2024.
  • Business Quant data shows Amortization - Goodwill for TEVA at $600.0 million in Q3 2024, $400.0 million in Q2 2024, and $700.0 million in Q2 2023.